TherapeuticsMD, Inc. Reports Q2 2026 Financial Results

What Happened
TherapeuticsMD, Inc. (NASDAQ: TXMD) filed a Form 8‑K on August 11, 2026 to report its results of operations and financial condition for the quarter ended June 30, 2026. The company issued a press release announcing its second quarter 2026 financial results; that press release is furnished as Exhibit 99.1 to the 8‑K and is incorporated by reference.

Key Details

• Press release dated and furnished on August 11, 2026 announcing financial results for the quarter ended June 30, 2026 (Exhibit 99.1).
• The 8‑K reports Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
• Exhibit 104 (Cover Page Interactive Data File, iXBRL) is included with the filing.
• No other material events such as executive changes, mergers, or bankruptcies were disclosed in this filing.

Why It Matters
This filing signals that TherapeuticsMD has publicly released its quarterly earnings and related financial information; those results can affect stock price and investor decisions. Retail investors should read the press release (Exhibit 99.1) for headline figures on revenue, profit/loss, and any guidance, and check the company’s subsequent SEC filings (e.g., 10‑Q) for full financial statements and notes. The Regulation FD disclosure indicates the company made the information broadly available to the public rather than selectively.